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ICER would be $53,964/QALY and the W would be $-362 (SD
3322). If the subjects were to improve after dropout, the ICER
would be $29,475/QALY and the W would be $3434 (SD 3309).
CONCLUSIONS: The results of cost-effectiveness analysis are
fairly robust to the choice of imputation scenario. While point
estimates indicate that over 4 years pramipexole is a cost-
effective alternative to levodopa, signiﬁcant statistical uncer-
tainty exists. The uncertainty associated with the assumptions
regarding post-dropout Qol is dwarfed by the uncertainty asso-
ciated with the ICER estimate.
SCREENING
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PATIENT PREFERENCES FOR COLORECTAL CANCER (CRC)
SCREENING STRATEGIES
Marshall DA1, Marshall JK1, Phillips KA2, Johnson RF3,Thabane L1,
Foster G1, O’Brien B1
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San Francisco, San Francisco, CA, USA; 3Research Triangle Institute,
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The success of population screening for CRC depends largely on
public uptake. Available strategies differ in multiple dimensions
of process and outcome. OBJECTIVE: To measure patient pref-
erences for CRC screening attributes and estimate willingness to
pay (WTP) for changes in attribute levels using a discrete choice
experiment (“conjoint analysis”). METHODS: Six key attributes
of CRC screening strategies were identiﬁed through structured
focus groups. Questionnaires included 10 choice sets based on a
fractional factorial design to maximize D efﬁciency. Surveys 
were mailed to a random sample of patients aged 40–60 years
from an Ontario primary care network (response rate = 51%
(547/1074), 88% of whom completed all 10 choice sets (n =
485)); b coefﬁcients from regression analyses estimated the mar-
ginal utilities of attribute levels from which WTP was calculated.
Differences among subgroups were tested using likelihood ratio
tests. RESULTS: Respondents had the strongest preferences for
sensitivity, with the highest utility for high sensitivity and the
lowest utility for low sensitivity. Individuals would be willing to
pay an additional CDN$910 (~US$640) for a test with high vs.
low sensitivity. Following sensitivity, respondents had the highest
preferences (in descending order) for speciﬁcity, preparation,
pain, and price. Preferences differed signiﬁcantly by gender, age
(<50yrs vs. >50yrs), income (<$50,000 vs. >$50,000) and edu-
cation (high school or less versus college or higher). In follow-
up questions for each choice set where individuals were asked if
they would prefer no test, 26% of respondents chose no testing
in more than 5 of their 10 choice sets. CONCLUSIONS: Results
show a wide range of marginal utility for attribute levels of CRC
screening tests, and many respondents preferred no test. Better
understanding of patient preferences can help improve the
design, promotion and uptake of CRC screening programs.
SC2
COST EFFECTIVENESS OF SCREENING AND STATIN
THERAPY IN CLINICAL GUIDELINES FOR CARDIOVASCULAR
PROPHYLAXIS
Milne RJ, Gamble GD
University of Auckland, Auckland, New Zealand
OBJECTIVES: To quantify the cost effectiveness of updated clin-
ical guidelines for risk screening and prevention of cardiovascu-
lar disease (CVD) with “statin” therapy in individuals free of
cardiovascular disease. METHODS: Risk proﬁles were collected
in 1992–1993 for 4704 men age 35–84y and 1216 women age
45–84y without CVD. Five-year risk of a cardiovascular hospi-
tal admission for each individual was estimated using a locally
validated Framingham risk equation. The predicted number of
incident events in 5 years was scaled to the 2001 NZ census pop-
ulation and integrated over age groups. In the base case, costs,
beneﬁts and cost effectiveness were estimated at screening age
thresholds of 45 for men and 55 for women (10 years younger
for smokers); concurrent treatment thresholds of 15% 5-year
cardiovascular risk and TC/HDLc = 4.5; and 5% discount rate.
RESULTS: In the NZ population of 784K men age 35–84y and
558K women age 45–84y, 72K men and 53K women would be
eligible for prophylaxis. Compared to no intervention, 5y pro-
phylaxis with 84% treatment adherence at a 15% treatment
threshold would avert 6716 incident cardiovascular events and
add 17,205 life years or 21,317 QALYs at an incremental cost
of $NZ70M. The base case ICER is $10,459 per event avoided,
$4083 per LYG or $3295 per QALY and it is sensitive to the
threshold lipid ratio, screening and treatment ages, risk thresh-
old, treatment efﬁcacy, 5y cardiovascular fatality, statin unit
price and the discount rate. CONCLUSIONS: Screening and
prophylaxis with statins is very cost effective at current drug
prices and clinically realistic screening and treatment thresholds.
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FACTORS IMPACTING MAMMOGRAPHY SCREENING IN
RURAL AND URBAN AREAS
Khan N
University of Illinois at Chicago, Chicago, IL, USA
OBJECTIVE: To compare mammography screening in rural and
urban areas and to assess the effect of various predisposing and
enabling factors on mammography screening. METHODS: Ret-
rospective self-reported cross-sectional data from Behavioral
Risk Factor Surveillance System (BRFSS) for year 2000 along
with county level contextual variables from area resource ﬁle
(ARF) were used in the analysis. The analysis was restricted to
females between 40–69 years of age. Logistic regression analysis
was performed using an indicator of mammography screening as
a dependent variable and race, age, rural dummy as independent
variables. Series of multiple logistic regressions adding predis-
posing and enabling factors consecutively to this model were
conducted. All the results were adjusted for complex survey
design. RESULTS: Seventy eight percent of women reported
having had a mammography within the last two years for routine
check up. Women living in rural area were less likely to be
screened for mammography as compared to women residing in
urban areas (OR = 0.80, CI = 0.72–0.86). This difference in
screening no longer persisted after controlling for predisposing
(smoking status, education level), enabling (income, insurance
status) and contextual level enabling factors (physician popula-
tion ratio). In general, women with higher education and better
ﬁnancial condition were more likely to screen. CONCLUSIONS:
Insurance status was one of the major determinants of mam-
mography screening for females residing in rural area. Avail-
ability of health care services also had an impact on screening
rates. In an environment where rural areas are faced with short-
age of health care services, the active participation of health care
workers like physicians in advocating use of screening services
becomes crucial.
SC4
ECONOMIC EVALUATION OF SCREENING FOR THE A-
ADDUCIN GENE VARIANT IN HYPERTENSIVE PATIENTS
Meckley LM,Veenstra DL
University of Washington, Seattle, WA, USA
OBJECTIVES: The purpose of this study was to determine
whether screening for the a-adducin gene variant among hyper-
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tensive patients is a cost effective method of preventing stroke
and myocardial infarction (MI) among patients not taking
diuretics. METHODS: A decision analytic model was developed
to compare the costs of antihypertensive therapy, stroke, and MI
for patients screened for the a-adducin gene variant versus those
not screened (standard care). The outcomes possible for each
group were: no event, stroke, or MI. Epidemiological data for
the risk of stroke, MI and the effect of the a-adducin gene variant
were obtained from the literature. We assumed patients in the
standard care group continued on their current anti-hypertensive
regimen. In the screened patient group, we assumed 90% with
the a-adducin gene variant switched to a diuretic, whereas those
with the wild-type a-adducin gene continued their current
regimen. Cost data were obtained from the literature, and the
cost of the screening test was estimated based on currently avail-
able commercial tests for other gene variants. The analysis was
conducted in 2003 dollars from the payer perspective. One-way
sensitivity analyses were performed to test the robustness of the
results. RESULTS: The screening strategy saved $1427 and
increased Quality of Adjusted Life Years (QALY) by 0.10. When
the screening test was assumed to cost $2000, the incremental
cost increased to $6600/QALY. When only 10% of patients were
assumed to have switched to diuretics based on their screen 
result the incremental cost effectiveness ratio increased to
$56,317/QALY. CONCLUSIONS: The results of this cost effec-
tiveness analysis suggest that under most circumstances, screen-
ing patients on antihypertensive therapy for the a-adducin gene
variant is a cost saving or cost effective strategy.
SESSION III
PRESCRIBING STUDIES
RX1
CLAIM-BASED DRUG WASTAGE ESTIMATION: HOW HIDDEN
REFILL BEHAVIOR CAN HELP
Xiao Q, Marks AS
Caremark Inc, Northbrook, IL, USA
OBJECTIVES: Dispensing large quantities of maintenance drugs
often causes concern of wastage due to patients changing med-
ication types. This study examines the prescription claims related
to patients changing medications, and establishes a new method
to estimate drug wastage and explores its implications on drug
dispensing policies. METHODS: The prescription claims of new
patients of three drug classes (satins, SSRIs and PPIs) in 2002
were extracted from Caremark’s prescription claim database.
Drug changes were identiﬁed and wasted days of supply were
calculated using the overlapped days between the new script ﬁll
date and the old script due date. The distributions of the wasted
days of the three drug classes in 90-day-supply reﬁlls at mail and
30-day-supply reﬁlls at retail were analyzed. Based on the ﬁnd-
ings, a separation process was developed to estimate average
wastage using clustering methods. RESULTS: The distributions
of the wasted days appeared to be bimodal. One component 
of the bimodal distributions was consistent with overlapping
pattern of non-changing drug reﬁlling patterns. The wastage
population identiﬁed two separate behavioral groups: reﬁll-
change people who change medications when their current med-
ications are due to reﬁll, and early-change people who change
medications even though they still have signiﬁcant amount of
existing medications. Reﬁll-change people were not likely to
waste medications. The new wastage rates were 0.4% in 90-
day supply and 0.2% in 30-day supply for statins, 0.2% in 90-
day supply and 0.5% 30-day supply for SSRIs and 1.2% in 
90-day supply and 0.9% in 30-day supply for PPIs. CONCLU-
SIONS: This study discovered a bimodal pattern in wastage. A
portion of the wastage implies hidden reﬁll pattern. Based on
these ﬁndings, this study establishes a new way to estimate pre-
scription drug wastage using claim data and shows that dis-
pensing large quantities does not necessarily lead to higher
wastage of medications.
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PREVALENCE AND CORRELATES OF POTENTIALLY
INAPPROPRIATE PRESCRIBING AMONG THE AMBULATORY
ELDERLY IN 2001
Viswanathan H, Bharmal M,Thomas III J
Purdue University, West Lafayette, IN, USA
OBJECTIVES: The study objectives were to determine the preva-
lence and correlates of potentially inappropriate prescribing
among the ambulatory elderly using 2003 Beers criteria.
METHODS: Retrospective analysis was conducted of the 2001
public use ﬁles of the National Ambulatory Medical Care Survey
and the National Hospital Ambulatory Medical Care Survey. A
total of 7243 visits by individuals over 64 years old with at least
one prescription were analyzed. The 2003 Beers criteria were
used to deﬁne potentially inappropriate medications irrespective
of disease, dose, and duration. Multivariate logistic regression
using generalized estimating equations was performed to
examine associations between age, gender, race, payment source,
reason for visit, referral status, sharing of care by other phy-
sicians, number of medications, ambulatory setting type, 
metropolitan location of practice, and geographic region with
potentially inappropriate prescribing. Data was analyzed using
SAS 8.2 and SUDAAN 8.02. An alpha of 0.05 was required for
signiﬁcance. RESULTS: Potentially inappropriate medications
were prescribed in 17.8 million ofﬁce-based ambulatory visits
and 930,211 hospital-based ambulatory visits, 11.9% of all
ambulatory visits made by the elderly. The most common drug
classes were narcotic analgesics, antihistamines, and antiar-
rhythmic agents. Among all variables examined, location of
practice, referral status, and number of medications were asso-
ciated with receipt of a potentially inappropriate medication.
After adjusting for other risk factors, visits made in metropoli-
tan areas or by referred patients were more than twice as likely
to involve a potentially inappropriate medication. In addition,
compared with patients taking one medication, those taking two
(Odds Ratio (OR) = 2.64, 95% CI = 1.41–4.95), three (OR =
6.85, 95% CI = 3.15–14.88), or four or more medications (OR
= 7.43, 95% CI = 4.36–12.67) were more likely to receive a
potentially inappropriate medication. CONCLUSIONS: Poten-
tially inappropriate prescriptions were prevalent in nearly 12%
of ambulatory visits made by the elderly in 2001. More prospec-
tive efforts to improve prescribing practices and prevent drug-
related problems among the elderly are needed.
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EVALUATING CLINICAL AND FINANCIAL OUTCOMES
ASSOCIATED WITH A RETROSPECTIVE DRUG UTILIZATION
REVIEW PROGRAM
Lee KY, Zajack L, Berdovich S, Bertram C, Bundek N
Walgreens Health Initiatives, Deerﬁeld, IL, USA
OBJECTIVES: Retrospective Drug Utilization Review (RDUR)
can be effective in reducing drug-related problems and adverse
health outcomes. This study examined whether RDUR interven-
tion letters to prescribers impacted the recurrence of drug-
prescribing programs (exceptions) and evaluated the subsequent
effect on utilization of health care services. METHODS: Data
used were from combined pharmacy and medical claims from
January 2002 through November 2003. To assess the impact of
